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Abstract
EphB receptors tyrosine kinases and ephrinB ligands were first identified as guidance molecules involved in the
establishment of topographical mapping and connectivity in the nervous system during development. Later in
development and into adulthood their primary role would switch from guidance to activity-dependent modulation of
synaptic efficacy. In sensory systems, they play a role in both the onset of inflammatory and neuropathic pain, and in the
establishment of central sensitisation, an NMDA-mediated form of synaptic plasticity thought to underlie most forms of
chronic pain. We studied wild type and EphB1 knockout mice in a range of inflammatory and neuropathic pain models to
determine 1), whether EphB1 expression is necessary for the onset and/or maintenance of persistent pain, regardless of
origin; 2), whether in these models cellular and molecular changes, e.g. phosphorylation of the NR2B subunit of the NMDA
receptor, increased c-fos expression or microglial activation, associated with the onset of pain, are affected by the lack of
functional EphB1 receptors. Differences in phenotype were examined behaviourally, anatomically, biochemically and
electrophysiologically. Our results establish firstly, that functional EphB1 receptors are not essential for the development of
normal nociception, thermal or mechanical sensitivity. Secondly, they demonstrate a widespread involvement of EphB1
receptors in chronic pain. NR2B phosphorylation, c-fos expression and microglial activation are all reduced in EphB1
knockout mice. This last finding is intriguing, since microglial activation is supposedly triggered directly by primary
afferents, therefore it was not expected to be affected. Interestingly, in some models of long-term pain (days), mechanical
and thermal hyperalgesia develop both in wild type and EphB1 knockout mice, but recovery is faster in the latter, indicating
that in particular models these receptors are required for the maintenance, rather than the onset of, thermal and mechanical
hypersensitivity. This potentially makes them an attractive target for analgesic strategies.
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Introduction
The discovery that members of the EphB subfamily of receptor
tyrosine kinases are involved in the formation of glutamatergic
synapses [1] led rapidly to the finding that these molecules are not
only required for axonal guidance and neuronal circuit assembly
during development, but are also involved in synaptic plasticity
during development and into adulthood. The majority of studies
on adult plasticity have focused on EphB-ephrinB interactions in
the onset and/or maintenance of long-term potentiation (LTP) in
different areas of the hippocampus, and in the striatum [2,3],
where significant advances in establishing mechanisms and
functional significance of Eph and ephrin involvement in synaptic
plasticity have been made using genetically modified mice [3]. The
use of transgenic mice proved necessary to study these molecules
for a variety of reasons, primarily linked to the binding promiscuity
of the different EphB receptors, and the bidirectional signalling
activated by EphB-ephrinB. There are 5 EphB receptors in
mammals (EphB1-4 and EphB6), which bind promiscuously with
3 transmembrane ligands (ephrinB1-B3)(see e.g. [4–6]). Despite
being conventionally called receptor and ligand, both EphBs and
ephrinBs activate intracellular signalling cascades (forward and
reverse signalling). The only tools currently available to interfere
with EphB-ephrinB interaction, EphB-Fc or ephrinB-Fc chimeras,
are not specific for a given receptor or ligand, and, whilst blocking
the activation of EphB receptors or ephrinB respectively, can also
bind to and activate ephrinBs or EphB receptors. The results
obtained in rats and wild type mice are therefore unavoidably
ambiguous, and studies in genetically modified animals are
currently essential to clarify mechanisms.
Synaptic plasticity in which EphB-ephrinB interactions are
involved has also been revealed at spinal cord level using models of
chronic pain, thus providing an alternative model for the study of
the link between molecular mechanisms and behavioural out-
comes (see e.g. [7–10]).
In many models of chronic pain, a fundamental mechanism
underlying enhanced responsiveness or spontaneous pain is central
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sensitisation, a mechanism which shares some features with
hippocampal LTP, implying enhanced transmission at synapses
formed by peripheral sensory afferents onto dorsal horn neurons;
to what extent LTP itself contributes to central sensitisation and
chronic pain is still debated (see e.g.[11,12,12–15]). Most, if not all,
forms of central sensitisation are thought to be NMDA –
mediated, but, despite three decades of research, controversy
remains as to the specific molecular mechanisms and the role of
NMDA receptor subunits, and even on the extent of NMDA
receptor involvement (see e.g. [16–19]). Furthermore, there is a
substantial body of evidence supporting the hypothesis that the
mechanisms underlying the onset of different forms of chronic
pain (e.g. inflammatory and neuropathic) as well as thermal and
mechanical hyperalgesia, differ, even if there are contradictory
findings also in relation to this issue (see e.g. [20–23]. It is clearly of
importance therefore a), to establish in full the molecular
mechanisms involved in the process of central sensitisation; b) to
determine to what extent the same mechanisms are common to
different types of chronic pain. This is essential to identify
therapeutic targets for the development of effective mechanism-
based analgesics hopefully with greater efficacy and fewer side
effects than those currently available. Clarifying the contribution
of EphB receptors to the spinal mechanisms of chronic pain would
help achieving these goals.
Previous work carried out in vivo on adult rats in our laboratory
demonstrated a requirement for spinal EphB receptor activation in
NMDA-dependent increases in synaptic efficacy, using two models
of chronic pain (formalin and carrageenan tests, [7]), and later
EphB receptors were shown to be involved in neuropathic pain
and the physical dependence on morphine [9,10,24]. Whereas in
the hippocampus LTP is mainly dependent on EphB2, we
suggested that in the spinal cord the primary receptor involved
in chronic pain would be EphB1 [7], an hypothesis strongly
supported by subsequent studies on EphB1 knockout (EphB1 KO)
mice, which reported a lack of thermal hyperalgesia in KO mice in
a model of neuropathic pain [25] and showed that EphB1 is
essential for the generation of LTP between C-fibres afferents and
dorsal horn neurons [26]. These findings suggest that a better
understanding of the role of EphB1 receptor in chronic pain could,
potentially, not only contribute to clarify the mechanisms
underlying central sensitisation in different pain models, but
provide an alternative therapeutic target for the treatment of
chronic pain of different aetiology.
The aim of the present work was to advance understanding of
the role played by EphB1 receptors in the onset of persistent pain,
using EphB1 KO mice. We hypothesised that, if NMDA-mediated
central sensitisation is indeed responsible for the onset of thermal
and mechanical hyperalgesia, as well as spontaneous pain, in
models of tissue injury, inflammatory and neuropathic pain, then
EphB1 KO mice should display blunted pain responses in all these
models. Furthermore, since NR2B phosphorylation and c-fos
upregulation are thought to be downstream of EphB receptors
activation ([27]; see also [7,8]), we hypothesised that we would
observe a reduction in NR2B phosphorylation and c-fos expres-
sion in KO mice in models of inflammatory pain, as we had
previously shown to occur in rats, if we blocked the interaction
between EphB receptors and ephrinBs ligands in vivo. We also
examined microglial activation in neuropathic pain. The mech-
anisms leading to microglial activation in neuropathic pain models
are still incompletely understood, but they appear to involve direct
activation by primary afferents, possibly via the release of ATP,
followed by activation depending on release of fractalkine from
neurons, cleaved by Cathepsin S of microglial origin [28]. None of
these mechanisms should be affected by the absence of EphB1.
Previous studies had not analysed normal sensory function in
EphB1 KO mice; there are no findings available from studies on
embryos suggesting a role for EphB1 in the development of
primary sensory afferents, but we deemed nonetheless essential to
ascertain anatomically, behaviourally, immunohistochemically
and electrophysiologically whether EphB1 deficiency caused any
major developmental alterations in the functional connectivity of
the sensory system. We were able to demonstrate that functional
EphB1 receptors are not essential for the development of normal
nociception, thermal or mechanical sensitivity, whereas, in
agreement with our hypothesis, they are required for the onset
and/or maintenance of thermal and mechanical hyperalgesia and
spontaneous pain behaviour in a variety of persistent pain models.
Surprisingly, microglial activation following nerve injury was
reduced in EphB1 KO mice. Of particular interest is the finding
that in some models of long-term pain mechanical and thermal
hyperalgesia develop both in wild type and EphB1 knockout mice,
but recovery is faster in the latter. This implies that in these models
EphB1 receptors are required for the maintenance, rather than the
onset, of hyperalgesia, and may therefore be useful therapeutic
targets for the development of new analgesics.
Materials and Methods
Ethical Approval
All experiments were undertaken in accordance with the United
Kingdom Animals (scientific procedures) Act 1986 (Project
Licence PPL 70/4774), and all efforts were made to minimize
animal suffering, and to reduce the number of animals used, in
accordance with the concept of ‘‘The Three Rs’’ (replacement,
reduction, refinement).
Animals
This study has been conducted on EphB1 null mutant mice.
Generation of the mutation has already been described [29]. We
used EphB12/2 mutants backcrossed for several generation in
the CD1 background to avoid possible confounding effects of
background genetic differences, and EphB1 lacz/lacz mutants
(expressing beta-galactosidase as a marker for EphB1 expression),
backcrossed for several generations in a CD1/129 background.
Aged-matched wild type (WT) littermates were used for compar-
ison. Male and females mice were housed up to five per cage on a
standard 12 hours light/dark cycle, with water and food pellets
available ad lib except during the testing period. Animals were
aged 12 to 15 weeks at the time of testing.
Animal Models
A number of models of acute and persistent pain were used, i.e.
the formalin test (a model of tissue injury [30], the Carrageenan
and Complete Freund’s Adjuvant (CFA) models of inflammation
and two models of neuropathic pain, chronic constriction injury
(CCI) and partial nerve ligation (PNL).
For the formalin test, 20 ml of formalin at a 5% concentration
(40% stock solution considered as 100%) were injected subcuta-
neously into the plantar surface of the right hind paw, using insulin
syringes with 0.33 mm needles.
For the Carrageenan model of inflammation, each animal
received a 20 ml injection of carrageenan (2% or 20 mg/ml
Carrageenan Lambda, Type IV, Sigma-Aldrich, Gillingham,
Dorset, UK) into the right hind paw.
For the CFA model of inflammation, 20 ml of CFA (Sigma F-
5881, Sigma-Aldrich) were injected into the plantar surface of the
right hind paw of the mouse.
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Chronic constriction injury (CCI or Bennett model) [31]: for all
animals, anesthesia was induced and maintained with 3%
isofluorane in 95% oxygen, 5% CO2 via a face-mask. The left
common sciatic nerve was exposed at the mid-thigh level and
proximal to the sciatic nerve’s trifurcation, and four ligatures with
chromic catgut were tied around it with about 1 mm spacing
between ligatures. Each ligature was tightened in order to reduce
the diameter of the nerve and retard, but not interrupt the
epineural circulation.
Partial sciatic nerve ligation (PNL or Seltzer model) [32]:
animals were anaesthetised as above. An incision was made in the
skin of the upper left leg and blunt scissors were used to part the
muscle layers to access the sciatic nerve. A tight ligation of between
K-M of the nerve was made using 6-0 mersilk suture (Ethicon,
Gargrave, North Yorkshire, UK). The skin was closed using 4-0
mersilk sutures (Ethicon). In sham animals, the surgery was
performed as described above, but the nerve was not ligated.
Behavioural Testing
All experiments were done during the day portion of the
circadian cycle only (06:00–18:00 h) and were performed blinded
to all test paradigms.
The Rotarod test was used to measure the balance and the
forced motor-coordination activity. We used a combination of
both accelerating and staggered Rotarod procedures on an
accelerating Rotarod (IITC Inc. Life Science, Woodland Hills,
CA) with a 32 mm diameter rod. On the first day the mice were
given a limited habituation of 5 min on a non rotating rod. Forty
eight h later they were tested 3 times at a rotating speed of 5 rpm
and the latency to fall was measured for up to 2 min, with a
30 min inter-trial interval back in their home cages, to limit the
effects of physical exhaustion. Every time a mouse was tested it was
placed on a non rotating rod, which was accelerated to a defined
rotating speed (5, 10, 20 and 30 rpm) with a constant incremental
slope. Any mice falling before the rod reached its full speed was
given 2 more chances. In case of 3 consecutive failures the given
score was 0. The test was performed on 4 different days, every
48 h.
The Hargreaves’ Plantar test (IITC Inc. Life Science) was used
to examine thermal sensitivity. Each mouse was housed separately,
in a randomly chosen compartment. A glass heating system
assured a standardized temperature of 22uC at the contact zone
between the plantar surface of the paw and the glass (baseline
temperature of the skin). Before the test, mice were habituated to
the experimental set-up for 2 h minimum on 2 consecutive days
prior and on the day of experiment. During the test, a heat source
was applied to the plantar surface of the hind paw, from
underneath and through the glass floor. The area tested was the
Figure 1. EphB1 KOmice have normal thermal and mechanical sensitivity. Bar charts illustrating the performance of EphB1 KO and WT mice
in a range of behavioural tests designed to measure motor performance (rotarod, A) or acute thermal (hot plate and Hargreaves, B and C) or
mechanical (von Frey, D) nociception. Behavioural analysis did not identify a significant difference between EphB1 KO and WT mice in any test. (t-test
in A for 10 and 30 rpm, C and D; Mann-Whitney U-test in A for 5 and 20 rpm and in B) A) 5, 10, 20 rpm WT n= 19, EphB1 KO n=29; 30 rpm WT n= 8,
EphB1 KO n= 16; B) WT n=16, EphB1 KO n= 25; C) CD1/ICR WT n= 24, EphB1 KO n=17, CD1/129 WT n= 13, EphB1 KO n= 12. Bars represent mean +/
2 SEM.
doi:10.1371/journal.pone.0053673.g001
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mid-plantar hind paw, in the area supplied by the tibial nerve,
avoiding the footpads, and was located by positioning a light spot
on the plantar surface of the paw. The stimulus and a timer to
record the reaction time were activated simultaneously. As soon as
the mouse removed its paw, the stimulus and timer were stopped.
After preliminary testing on control mice (WT CD1-ICR and
CD1/129), the light intensity was set at 18% of maximum, in
order to achieve a baseline of 10 to 20 seconds. The minimum
resting period between each successive exposure was 5 min for
alternate paws or 10 min for the same paw, to minimize the effects
of repeated exposures. Two to 4 measurements were collected for
each paw, depending on their reproducibility. For the data
presented in figure 1, control WT and EphB1 mice were tested 3
times on 3 different days, with at least 2 days rest between test
days. To examine the development of thermal hyperalgesia in
inflammatory and neuropathic pain, animals were tested before
treatment, and 90 and 150 min after carrageenan or saline
injection [33], on day 1, 2, 5, 7, 9 and 14 after CFA or saline
injection and at 3, 5, 7, 10, 14, and 21 days after PNL.
For the Hotplate test for thermal sensitivity, on the previous day
and just before testing, mice were habituated for 10 minutes in the
Hot Plate Plexiglas box (IITC Inc. Life Science). Mice from the
same rearing box were habituated together, to minimize stress.
After habituation, mice were placed individually on the hot plate,
heated at either 50 or 55˚C, and the latency to first sign of paw
licking or escape jumping was recorded as an index of the pain
threshold. The experiment was performed 3 times with 48 h
between two measurements. A stimulus cut-off of 45 s and 1 min
were used respectively when testing at 55 and 50uC to avoid any
paw damage.
Mechanical sensitivity was tested using von Frey Hairs. To
determine the baseline threshold for mechanical sensitivity for the
mice used in our experiments (baseline mechanical sensitivity
varies considerably in mice depending on genetic background), we
used a series of 6 calibrated nylon monofilaments (Touch-Test
Sensory Evaluator, Semmes-Weinstein Monofilaments) chosen
with equal spacing (s= 0.34 on average) on the log-dose scale,
ranging from 0.04 g to 4.56 g. The mice were placed in individual
plastic compartments on a stand with a metal mesh floor, and the
von Frey hair applied perpendicularly to the plantar surface of the
paw until it buckled slightly (minimum 20%), and maintained for 6
seconds. The next stimulus was presented as soon as any
behavioural response due to the previous one was resolved. A
positive response was recorded when the mouse sharply removed
its paw, often followed by shaking and even licking [34]. Flinching
immediately upon application or removal of the hair was
considered a positive response. When assessing the baseline paw
withdrawal threshold, each monofilament was applied five times
on each paw at 5 min interval. The withdrawal threshold
corresponded to the force in g at which the mouse withdrew the
paw in minimum 5 out of 10 trials (combining the results of
contra- and ipsi- lateral paws). Data for figure 1 were collected
using this method. For all subsequent experiments (carrageenan
and CFA i.pl. injection, neuropathic pain models) we adopted
instead the up-and down method described by Chaplan et al. [34],
which allows interpolation of the mechanical threshold (stimulus
intensity at which the mouse would respond 50% of the times) with
fewer applications of the von Frey filaments, and was therefore
more suitable for these tests, inducing less stress in the animals.
The up-and-down method requires prior knowledge of baseline
mechanical threshold, so it could not have been applied in our
initial experiments. Animals were tested before treatment, and 90
and 150 min after carrageenan or saline injection [33], on day 1,
2, 5, 7, 9 and 14 after CFA or saline injection, at 3, 5, 7, 10, 14,
and 21 days after PNL Mechanical and at 7, 14 and 21 days after
CCI.
For the Formalin test mice were housed in a square test box,
maintaining a constant temperature of 22uC at the plantar surface
of the paw [35]. Three out of the four sides of the box were
mirrors, to simplify the observation and characterisation of the
different behaviours recorded. Mice were habituated to the
experimental environment for 30 min on two different days, and
15 min on the day of experiment. After formalin injection, mice
were immediately transferred into the box and nocifensive
responses (Lifting/Favouring; Licking/Biting) related to the
injected hind paw, recorded in 5 min blocks for 1 h. A ‘painscore’
was then calculated according to the formula PS = (Time spent in
full weight bearing position * 0)+(time spent lifting or favouring *
1)+(time spent licking or Biting * 2)).
Immunohistochemistry
Mice were deeply anesthetized with pentobarbital (140 mg/kg,
i.p.) and perfused transcardially with heparinised saline (0.9%
NaCl) followed by 0.1M pH 7.4 phosphate buffer (PB) containing
4% paraformaldehyde (PFA). The left and right L4 and L5 lumbar
dorsal root ganglia (DRGs) and/or lumbar spinal cords were then
dissected and stored in 4% PFA overnight. The following day
tissues were transferred in 20% sucrose in 0.1M PB, pH 7.4 for
24 h at at 4uC and then blocked in O.C.T. (Optimum Cutting
Temperature) embedding matrix (BDH, Essex, UK) in liquid
nitrogen and stored at 280uC. In all studies, 2–5 slides from each
animal were used for the staining. 2 slides were randomly chosen
as negative control for the staining process, 1 slide was coated only
with primary antibody and the other with secondary antibody
only. 15 mm thick transverse sections of L4 and L5 DRGs
(perpendicular to the neuronal axis of the DRG) or 30 mm thick
lumbar spinal cord section (L3-4, where afferents from the mouse
hind limb preferentially terminate, see [36]) were cut on a Bright
microtome 5040, mounted on slides (Superfrost Plus, BDH)
sequentially, allowed to dry at room temperature for 30 min and
then preserved in cryoprotectant (30% sucrose w/v, 30% ethylene
glycol w/v in 0.01M phosphate buffer saline (PBS) at –20uC.
Lumbar DRG staining: three randomly chosen left or right
DRGs from intact EphB1 KO mice and three randomly chosen
left or right DRGs from intact WT mice were used, and slides
were chosen from each animal so that 5 roughly equidistant
sections taken from the entire length of the ganglion would be
examined for each staining. The slides were then processed with
conventional immunofluoscence techniques. To identify the
proportion of peptidergic nociceptive neurons in the DRGs, the
sections were stained for CGRP using primary antibodies rabbit
anti-CGRP (Sigma c8198) at 1:1300 and, to stain all neurons, with
the general neuronal marker mouse anti-bIII-tubulin (Promega,
Southampton, UK, 1 mg/ml) at 1:1200 with secondary antibodies
donkey anti-mouse CyIII (Jackson Immunochemicals, West
Grove, PA, 1.3 mg/ml) and donkey anti-rabbit FITC (Jackson,
1.4 mg/ml). Non peptidergic nociceptive neurons were identified
on the basis of their binding to isolectin B4 (IB4). IB4-biotin (Sigma,
0.5 mg/ml) was used in the concentration 1:500 together with
mouse bIII-tubulin (Promega, 1 mg/ml) at 1:1200. As secondary
antibodies, donkey anti-mouse FITC (Jackson, 1.4 mg/ml) at
1:200 and anti-IB4 TRITC (Sigma, 2 mg/ml) at 1:200 were used.
Large, mainly proprio- or mechanoceptive, neurons were stained
using mouse N52 antibody (Sigma) at 1:400 and the general
neuronal marker rabbit protein gene product (PGP) 9.5 (Abcam,
Cambridge, UK) at 1:400. The secondary antibodies used were
donkey anti-rabbit FITC (Jackson, 1.5 mg/ml) at 1:200 and
donkey anti-mouse CyIII (Jackson, 1.3 mg/ml) at 1:1000. The
EphB1 Receptor Deficiency Lessens Chronic Pain
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slides were then washed with 0.01M PBS (365 min) and covered
with 22650 mm Borosillicate glass cover slips (Calbiochem, San
Diego, USA) using FlurosaveTM Reagent (Sigma, St. Louis, MO,
USA). All antibodies were diluted using 0.01M PBS with 0.2%
Triton X (w/v) and 0.1% (w/v) of sodium azide.
Spinal cord sections: to examine the anatomical integrity of
nociceptive afferent terminals in the dorsal horn of the spinal cord,
the spinal cords from 3 WT and 3 EphB1 KO mice were
dissected. 3 slides were then randomly chosen from each animal
and double-stained for CGRP and IB4. Sections were stained for
CGRP using as primary antibody a rabbit anti-CGRP (Sigma
c8198) at 1:1400 with secondary antibody Goat anti-rabbit
Alexafluor 546 (Molecular Probes, Eugene, OR, USA). IB4-biotin
(Sigma, 0.5 mg/ml) was used in the concentration 1:500 and as
secondary Extravidine FITC at 1:500. To examine the effect of
inflammation or tissue injury on the expression of c-fos, the spinal
cords of 12 WT and 12 EphB1 KO mice were dissected out. Both
WT and KO mice had been assigned randomly to one of 4
treatment groups: 1) saline i.pl injection 1 h prior to culling; 2)
formalin i.pl. injection 1 h prior to culling; 3) saline i.pl. injection
3 h prior to culling; 4) carrageenan i.pl injection 3 h prior to
culling; all injections were performed as described previously. Two
slides were randomly chosen from each animal, then coated with a
primary antibody rabbit anti-c-fos (1:2500) (Invitrogen, Paisley,
UK) and a secondary antibody Alexafluor 488 goat anti-rabbit
IgG (1:1000) (Molecular Probes). For assessment of microglial
activation following PNL, 4–5 sections of spinal cords from WT
and KO mice were randomly collected 3,7,14 and 21 days after
lesion. Sham operated animals acted as controls. Slides were
coated with Rabbit anti Iba1 (Wako, Japan) 1:1000, followed by
Goat anti rabbit IgG Alexa fluor 546 (Molecular Probes A11035)
1:1000. All antibodies were diluted to working concentrations with
0.01M PBS with 1% (w/v) TritonX and 0.01% (w/v) sodium
azide.
Image Acquisition and Analysis
All images were acquired using a Zeiss fluorescence microscope
(Axioplan 2 or Imager Z1) with a 206 objective with a Zeiss
Axiocam HRm (Carl Zeiss, Goettingen, Germany), using Axiovi-
sion 40LE version 4.2 software (Carl Zeiss). All analysis was
performed with the investigator blinded to genotype and
treatment.
Lumbar DRGs: Two randomly chosen pictures were taken
using a Zeiss Axioplan 2 microscope. All stained cells with visible
nuclei were counted, first in sections stained with the general
neuronal marker, then in sections stained with the subpopulation-
specific marker. For each animal, 5 sections were counted for each
staining, for a total of 15 sections per animal. A total of 43660 cells
were counted for WT, and 47827 cells for EphB1 KO mice.
Spinal cords: to quantify nociceptive afferents in the dorsal
horn, photomicrographs of sections stained for CGRP immunor-
ectivity or IB4 binding were taken using a Zeiss Imager.Z1
microscope. The surface of the stained area was measured using
the outlining application in Axiovision 40LE version 4.2 software
(Carl Zeiss). Immunoreactive c-fos expressing cells were counted in
Laminae I and II of the ipsilateral (injected) side of the lumbar
spinal cord grey matter.
To study microglial activation, usually 5 (or a minimum of 4)
sections from each animal were chosen at random. Four boxes
measuring 104 mm2 were placed onto areas of the lateral, central
and medial dorsal horn. The mean number of Iba1 positive cells,
morphologically identified as activated microglia, was determined
within this area [37]. All spinal cord sections were examined using
a Zeiss Axioplan 2 microscope.
Western Blot and Immunoprecipitation
Animals were divided into saline, CFA, carrageenan and
formalin treated groups for both genotypes. The mice were culled
and hemisected lumbar spinal cord tissues were rapidly removed
at 60 minutes after formalin injection, 3 hours after carrageenan
and 14 days after CFA. Saline controls were taken at the same
time as their treated counterpart. Tissues were frozen in liquid
nitrogen and stored at 280uC until use.
Each sample, obtained pooling the tissues from two mice, was
homogenized on ice using an Ultraturax (IKA) homogeniser in
300 ml of NP-40 lysis buffer (1% Nonidet P-40, 150 mM NaCl,
500 mM Tris-HCl pH8, 1 mM EDTA, 0.5% SDS, adding 256
Protease inhibitor cocktail (Complete Roche), 100 ml leupetin
(10 mg/ml), 100 ml phosphatase inhibitor cocktail 2 (Sigma),
200 ml NaF (250 mM stock) mix and 100 ml (1 mM final) PMSF
to each 10 ml of buffer). 26300 ml of lysis buffer was added to
wash the Ultraturax to collect all the homogenate. The Ultraturax
was also cleaned with ethanol and ddH2O between each sample
homogenization. The homogenates were placed in a carousel for 2
hours at 4uC before being centrifuged at 12000 rpm for 20
minutes at 4uC. The supernatants were collected and the protein
concentrations were determined using a detergent-compatible
assay (BCA-Pierce kit) with a bovine serum albumin (BSA)
standard in a Dynex reader (Dynex Technologies, Inc. Chantilly,
VA).
For immunoprecipitation, total lysates (1 mg) were incubated
with 5 ml of goat anti-NR2B IgG (Santa Cruz Biotechnology,
Santa Cruz, CA, 0.2 mg/ml) on a carousel overnight at 4uC,
followed by incubation with 50 ml of Protein G- Sepharose slurry
(1:1, Santa Cruz Biotechnology) at 4uC for 2 hours in agitation
and further centrifugation at 5000 rpm for 2 minutes. Superna-
tants were discarded and Sepharose beads were washed 3 times
with 1 ml of lysis buffer; with vigorous vortex and brief spin at
5000 rpm after each wash. 40 ml of 2 times SDS sample buffer was
added to each sample, then vortexed and heated at 95uC for 5
minutes, before 5 minutes centrifugation at 12000 rpm. The
immunoprecipitation samples were then kept at 220uC until
loaded.
For western blot analysis, proteins (1 mg) were resolved on 8%
SDS-PAGE gels run in migration buffer (3 g Tris-base, 14.4 g
glycine, 1 g 1% SDS for 1litre) for 90 minutes at 90V and loaded
along with controls (using normal goat serum) and full range
rainbow recombinant marker (Amersham Biosciences, Arlington
Heights, IL). Transfer was run in buffer (100 ml migration buffer
(without SDS), 200 ml methanol, 700 ml H2O for 1 litre) for an
hour at 100V using nitrocellulose membranes (Amersham) and a
Trans-Blot Transfer Cell system (Bio-Rad, Hercules, CA) to which
an icebox was added to avoid overheating and damage to the
membrane. The blots were blocked at room temperature for
1 hour on agitation with 4% BSA in TBS-T (2.42 g Tris base, 8 g
NaCl, adjust PH = 7.6 with HCl, 0.5 ml Tween 20, adding H2O
for 1 litre) and the membrane incubated with two primary
antibodies: mouse a-p-Tyr (1:2000 TBS-T; Santa Cruz Biotech-
nology) and rabbit anti-NR2B IgG (1:1000 TBS-T; Upstate 1 mg/
ml) in a polythene container overnight at 4uC. The membrane was
then washed 3 times for 10mins in TBS-T before being incubated
with the secondary antibodies, goat anti-mouse IR680 and donkey
anti-rabbit IR800 (both 1:15,000–20,000 in TBS-T) for 1 hour on
agitation. Revelation was carried out using the Odyssey Lyca
Scan.
Electrophysiology
Mice were given an initial dose of 1.8 g/kg urethane i.p. and
15 min later, 0.4 g/kg for sustained anaesthesia. Rectal temper-
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ature was maintained at a mean of 36–38uC. After tracheotomy,
mice were supported prone by clamps at T13 and L3/4. L1-2
laminae were removed, the dura opened, and the tissues covered
by 4% saline-agar which was subsequently removed over the SC
and the pool filled with paraffin oil. The sciatic nerve was exposed
for stimulation in-continuity in the popliteal fossa, and the sural
nerve freed and sectioned distally for stimulation. Sciatic nerve
stimulation involved low and medium threshold fibres from muscle
and skin, whereas stimulation of the sural nerve provided solely a
cutaneous input. We did not stimulate at C-fibre strengths for the
comparison of WT and KO mice because preliminary experi-
ments failed to reveal consistent reliable field potentials in
recordings from the cord dorsum. In the rat, the antecedent
volleys in the lower threshold A-fibres can inhibit C-fibre evoked
field potentials which can be revealed better using TTX to block
A-fibres leaving conduction intact for a group of TTX-resistant
unmyelinated fibres [38]. However, the procedures were consid-
ered impractical to allow a valid comparison of WT and KO mice
with the limited numbers of mice available for this part of the
study.
Stimulation was via bipolar Platinum hook electrodes with 0.05
or 0.1 ms square wave voltage pulses (Digitimer DS2) at 2 Hz and
the intensity set at 56threshold (5T) for the systematic comparison
of WT and KO mice. A plastic ensheathed 100 mm diameter Pt.
wire was used for focal recording at the cord dorsum surface with
the reference electrode on nearby muscle. The spatial distribution
of the evoked potentials was then determined at the root entry
zone (REZ) in 200 mm steps from the rostral end of T13 to the
caudal end of L2 vertebral levels (the location of the epicentre of
the hind limb representation; cf. [39]). At each site, 20 evoked
responses were recorded through a FET-follower head stage and
fed to a high-gain AC-couple differential amplifier (Digitimer
DL150) with HF bandwith at 10 or 3 kHz and TC 30 ms. Signals
were fed to a CED interface, sampled at 20 kHz and the average
of 20 responses derived for each site using Spike2 software.
Statistical Analysis
Data are expressed as mean6 S.E.M. Behavioural, biochemical
and immunohistochemical studies were statistically analyzed with
one-way or two-way analysis of variance (ANOVA; for repeated
measures for behavioural tests) followed by post-hoc multiple
comparisons testing with the Holm-Sidack method. ANOVA on
ranks was used when the data failed the normality or equal
variance tests. t-test or Mann-Whitney U-test as appropriate were
employed to compare two groups. A p value ,0.05 was
considered to be statistically significant. All statistical analyses
were performed using ‘‘SigmaStat for Windows’’ (version 2.0;
Jandel Corporation, San Rafael, CA, USA). For the electrophys-
iological data, a mixed design two-way ANOVA (SPSS statistical
software) was used with the between factor set as WT or
EphB1KO and the within factor as level of the spinal cord.
Additional post-hoc analysis (independent t test or Mann-Whitney
Rank Sum test) was done at each position along the rostro caudal
axis.
Results
EphB1 KO Mice Respond Normally to Acute Pain Stimuli
and their Small Diameter Primary Sensory Afferents are
Anatomically Intact, Although Changes in Connectivity of
Larger Diameter Cutaneous Fibres were Observed
Locomotor coordination. A prerequisite for any behaviour-
al study of an animal’s susceptibility to noxious and non-noxious
stimulation in models of chronic pain is an intact functioning
motor system. Therefore, prior to the systematic use of a number
of established tests of acute nociception to assess the functional
integrity of primary nociceptive afferents, we examined proprio-
ception, coordination and tactile sensibility in WT and KO mice
as an aspect of locomotion using the Rotarod test. (figure 1A). The
scores revealed no clear differences between the two groups save
perhaps for a slight trend towards a reduced performance in the
KO mice at lower rotation speeds, but this did not reach
significance.
Acute thermal nociception was assessed using a radiant heat source
applied to the plantar surface of the hind paw (Hargreaves test) or
a hot plate (figure 1B–C). Mechanical sensory thresholds were assessed
manually using von Frey hairs (figure 1D). Neither acute thermal
nociception or the response to mechanical stimulation differed
significantly in WT and KO mice. These behavioural results
confirmed our previous finding of a lack of involvement of EphB1
receptors in acute nociception, and indicated the functional
integrity of nociceptive pathways, despite the absence of functional
EphB1.
Immunohistochemical analysis of primary sensory
afferents. We further confirmed the anatomical integrity of
primary sensory afferents by immunohistochemical analysis of
lumbar DRGs and nociceptive terminals in the dorsal horn of the
spinal cord. DRGs were double-stained with a general neuronal
marker (PGP9.5 or beta-tubulin) and a marker for either
peptidergic or non-peptidergic nociceptive neurons, respectively,
using anti-CGRP antibodies or the isolectin IB4. The proportions
of DRG neurons stained with the different markers were
calculated by counting both the total number of nucleated
neurons, and the number of CGRP or IB4- positive neurons,
present in randomly chosen sections. There were no differences
between wild type and EphB1 KO mice in the proportion of DRG
neurons stained with the two different markers (table 1). Similarly,
nociceptive afferent terminations were examined after staining
lumbar spinal cord sections with anti-CGRP antibodies and the
isolectin IB4. Again there was no significant difference in the area
occupied by nociceptive afferents in the dorsal horn of the spinal
cord in wild type and EphB1 KO mice (table 1), suggesting
anatomical integrity of these primary afferents terminations in the
mutant mice, in agreement with their normal acute nociception
(figure 1B–C).
Large mechanoceptive and proprioceptive DRG neurons were
stained with N52 antibodies, which recognise high molecular
weight neurofilament and again there was no difference in the
proportion of neurons in the DRGs between WT and EphB1 KO
mice (table 1) in agreement with their normal mechanical
sensitivity and normal motor behaviour, which requires intact
vestibular, propriospinal and tactile sensation (Figure 1A and 1D).
Electrophysiological comparison of afferent transmission
in WT and KO Eph.B1 mice. Further evidence concerning the
functional status of primary afferent pathways in these KO mice
relates to the somatotopic organisation and synaptic transmission
to 2nd or higher order neurones. This was determined electro-
physiologically by measuring the spatial distribution and ampli-
tudes of the compound action potentials (CAPs) and field
potentials (FPs) evoked at the cord dorsum by electrical stimulation
of the sciatic and sural nerves (figure 2). For comparison of the WT
and KO mice the stimulus intensities were set at 56T where T is
the threshold of the lowest threshold fibre in the stimulated nerve
conducted to the root entry zone. For the sciatic nerve this
threshold is that of the fast conducting primary afferent fibres
(Group1A) from muscle spindles in the calf and foot, whereas for
the sural nerve the threshold is that of Ab fibres cutaneous fibres
innervating the lateral plantar surface of the foot. The epicentre of
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the hindlimb representation lay under the L1 vertebra. No
significant differences between WT and EphB1KO mice were
observed either in the spatial profile or peak amplitudes of the
evoked-CAPs and FPs with stimulation of the sciatic nerve
(p.0.05; data not shown), nor in the evoked-CAPs with
stimulation of the sural nerve (figure 2A). Interestingly, however,
with stimulation of the sural nerve the peak amplitudes of the FPs
were highly significantly increased by approximately threefold in
the KO as compared to WT (P,0.001; figure 2B) and this was
manifest over the entire spatial array of recordings. This suggests
that the lack of EphB1R during development resulted in changes
in spinal connectivity of the large and medium-sized cutaneous
Ab/d fibres in the superficial dorsal horn.
Persistent Pain Behaviour Following Tissue Injury is
Significantly Reduced in EphB1 KO Mice
We then tested WT and EphB1 KO mice in a model of
persistent pain, the formalin test. Spontaneous pain behaviour
elicited by the injection of a diluted solution of formalin in the
plantar surface (i. pl.) of the hind paw was recorded for 60 min.
We recorded both licking and lifting/favouring of the injected
paw, which we then combined to obtain a pain score (figure 3).
The response following formalin injection can be divided in two
phases. Phase I, corresponding to acute nociception, lasts about 10
minutes, and during this phase no significant difference was
observed between WT and EphB1 KO mice. A short interval then
occurs, during which the animal displays no signs of spontaneous
pain, followed by Phase II, the resumption of pain behaviour,
lasting for 30 or more minutes, depending on mouse strain. In
part, Phase II is attributed to central sensitisation. EphB1 KO
mice displayed significantly less spontaneous pain behaviour in
Phase II of the formalin test as compared to their WT counterparts
(p,0.05).
EphB1 Receptor Expression is Required for the Onset of
Short-term Inflammatory Pain and EphB1 Deficient Mice
Recover Significantly Faster from Thermal Hyperalgesia
and Mechanical Allodynia in a Long-term Model of
Inflammation
Peripheral tissue inflammation can lead to the onset of persistent
(chronic) pain, mediated by mechanisms including peripheral and
central sensitisation.
We used two tests of inflammatory pain, of shorter and longer
duration (carrageenan and CFA injection in the hind paw
respectively), to assess the role played by EphB1 receptor in the
onset of inflammatory pain. Thermal and mechanical responses
were measured before and after i.pl. injection with carrageenan
and CFA (figure 4). The onset of both thermal hyperalgesia and
mechanical allodynia was delayed and depressed in EphB1 KO
mice in the carrageenan test (figure 4A). Thermal hyperalgesia was
assessed in two strains of mice (CD1 and CD1/129), since it is well
established that thermal and mechanical sensitivities depend on
genetic background in mice. The results were similar, even if
prevention of thermal hyperalgesia was more complete in the
strain which developed a less pronounced hyperalgesia in the WT
mice (CD1/129, figure 4A). The latency to paw withdrawal to
thermal stimuli was significantly decreased already at 90 min after
carrageenan injection in WT animals for both strains (p,0.05),
whereas there was no significant decrease in EphB1 KO, again
regardless of strain. In the CD1 strain of mice tested only the WT
mice developed allodynia (p,0.05), none being present in the
EphB1 KO.
In the longer duration CFA injection model, responses to
thermal and mechanical stimuli were recorded at 1, 2, 5, 7, 9 and
14 days after CFA injection (figure 4B). Both WT and EphB1 KO
mice developed thermal hyperalgesia, but whilst the latency to
paw withdrawal remained significantly lower than baseline values
for the duration of the experiment in WT (p,0.05), by day 9 in
EphB1 KO mice these latencies had returned to values not
significantly different from baseline. Both WT and EphB1 KO
developed significant (p,0.05) and persistent mechanical allody-
nia, but the thresholds remained significantly lower for WT
animals at 9 and 14 days (p,0.05), again indicating a faster
recovery for EphB1 KO from day 9.
The Increase in the Number of c-fos Expressing Cells in
Laminae I and II of the Dorsal Horn, which Follows i.pl.
Injection with Formalin or Carrageenan, is Significantly
Smaller in EphB1 KO Mice
C-fos expression in dorsal horn neurons is considered as an
indicator of activation of nociceptive pathways. We counted the
number of c-fos expressing neurons in laminae I and II of the
dorsal horn in immunostained sections of spinal cord of animals,
which had received a unilateral i.pl. injection of saline, formalin or
carrageenan (figure 5). A large and significant (p,0.05) increase in
the number of c-fos expressing neurons was observed in WT mice
Table 1. Lack of alteration in DRG neurons and dorsal horn immunoreactivity in EphB1 KO mice.
Table 1 WT (n=3) EphB1 KO (n=3)
DRGs % of CGRP positive neurons 31.8+/20.01 30.6+/20.04
% of IB4 binding neurons 34.5+/20.021 34.9+/20.03
% of N52 stained neurons 35.8+/20.027 36.7+/20.038
Dorsal
Horn
Area covered by CGRP-immunoreactive terminals (m2) 38899.8+/21528.489 39645.3+/2884.572
Area covered by IB4-binding terminals (m2) 24026.1+/21472.583 24325.3+/2440.958
Sections of lumbar L4 and L5 DRGs were double-stained with markers for the different subpopulation of neurons in the DRG and a general neuronal marker (PGP9.5 or
beta-tubulin). Anti-CGRP antibodies and the isolectin IB4 bind respectively to peptidergic and non-peptidergic small and medium sized nociceptive neurons, whereas
N52 antibodies bind to high molecular weight neurofilament present in large mechanoceptive and proprioceptive neurons. Quantification of the proportion of the total
number of neurons (identified by the general neuronal marker), which also stained for a specific subpopulation marker, was carried out. No difference was observed
between WT and EphB1KO mice. Sections of lumbar spinal cords were stained with anti-CGRP antibodies of the isolectin IB4, which bind respectively to the terminals of
peptidergic and non-peptidergic nociceptive afferents. No difference was observed between WT and EphB1KO mice in the area covered by CGRP-positive and IB4-
positive terminals in the dorsal horn of the spinal cord.
doi:10.1371/journal.pone.0053673.t001
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following formalin and carrageenan injection, as compared to
saline treated WT mice. A significant increase in c-fos expression
was also present in formalin or carrageenan treated EphB1 KO
mice, but this was significantly smaller than in WT (p,0.05).
The NR2B Subunit of the NMDA Receptor is
Phosphorylated in WT, but not EphB1 KO Mice following
Formalin or Carrageenan Injection
To examine further the role of the NMDA receptor in EphB/
ephrinB signalling, we measured the phosphorylation state of its
NR2B subunit in spinal dorsal horn preparations of WT and
EphB1 KO mice, after i.pl. injection with saline, formalin
carrageenan (figure 6). NR2B was immunoprecipitated from the
spinal cords, and western blotting was performed using anti-
phosphotyrosine antibodies, followed by anti-NR2B antibodies to
measure total NR2B. Levels of phosphorylation were calculated
using densitometry. Both carrageenan and formalin injection
caused a significant increase in tyrosine phosphorylation of the
NR2B subunit in WT (p,0.05), but not in EphB1 KO mice.
Deletion of the EphB1 Receptor Gene Reduces, but does
not Abolish, Mechanical Allodynia in Two Models of
Neuropathic Pain and Thermal Hyperalgesia in the
Seltzer Model
We examined the development of mechanical allodynia in two
models of neuropathic pain, the PNL and CCI models (figure 7).
The CCI model has a more marked inflammatory component.
Animals with PNL were tested 3, 5, 7, 10 14 and 21 days after
injury. Both genotypes developed thermal hyperalgesia following
injury, but its development was significantly less marked in EphB1
KO mice. In WT mice, thermal hyperalgesia developed from the
first day of testing (3 days after injury) and persisted throughout the
duration of the experiment. In EphB1 KO mice, the reduction in
paw withdrawal latency was significantly smaller than in WT mice
at all time points, except 5 days after injury. The mice also
developed signs of mechanical allodynia with a marked decrease in
the threshold of the response (lifting response to tactile stimulation)
of the injured paw as compared to baseline (see figure 7). This
increased mechanical sensitivity was markedly reduced in EphB1
KO mice when compared to WT at all time points (p,0.05).
A more complete prevention of development of mechanical
allodynia was observed in the CCI model. Animals were tested at
7, 14 and 21 days after injury. WT mice developed a significant
mechanical allodynia by 7 days (p,0.05), and this persisted
throughout the experiment, whilst EphB1 KO mice failed to
develop a significant mechanical allodynia. Note that autotomy
was not observed in any of the animals. Sham operated animals
did not develop significant hyperalgesia or allodynia in either
genotype (results not shown).
For CCI injured mice, we verified that the behavioural
difference between WT and KO mice was not due to differences
in the extent to which the animals were affected by the injury: we
stained DRG neurons with ATF3 (a marker of axonal injury), and
IB4 (a marker for small, non peptidergic, nociceptors), and sections
of dorsal horn were stained with IB4. In both genotypes, CCI
caused a similar and significant (p,0.05) increase in the number of
DRG neurons with ATF3+ nuclei in the injured compared to the
uninjured side (uninjured, 0.09+/2.057 for WT and 0.109+/
2.0711 for EphB1 KO; injured, 15.5+/21.231 for WT and
12.1+/24.113 for EphB1 KO). There was no change in the
proportion of IB4+ neurons in the injured DRG, but a loss of IB4+
terminals in lamina II of the dorsal horn was observed, in a lateral
position (data not shown). C-fos activation in the dorsal horn was
absent at 28 days after injury in both genotypes (data not shown).
Figure 2. EphB1 KOmice display enhanced A-fibre evoked field
potentials along the cord dorsum. Electrical stimulation of the
central end of the cut sural nerve at 5T typically evoked a synchronous
triphasic compound action potential (CAP), followed by a negative field
potential (FP) at the root entry zone. Recordings were made
systematically along the rostro-caudal axis 200 mm apart. At each site,
20 successive responses were averaged and the amplitudes (Voltsx10-4)
plotted as a function of their rostro-caudal distribution. CAP values
were normalised (amplitude and distribution) so allowing comparison
of resulting FPs to inputs of similar strengths. Top and bottom panels
respectively show the spatial distribution of the CAP and FP amplitudes,
with the mean evoked-potentials at each successive position indicated
by the paired histograms (WT: filled column; EphB1KO: empty column).
While no statistical difference was found between genotypes in the
amplitude of the evoked-CAPs (mixed design two-way ANOVA,
between factors, p.0.05), the distribution of the evoked-FPs (bottom
panel) along the rostro-caudal axis of the cord was significantly
different between WT and EphB1KO mice (between factors, p,0.001),
indicating that knocking out the EphB1 gene produced profound
alterations in the amplitude of Ab/Ad fibre-mediated synaptic
responses of the dorsal horn neurones in EphB1KO mice. For both
types of evoked-potentials, a significant effect (p,0.001) was present
for the within factor (level of the spinal cord) indicating that they differ
along the rostro-caudal axis of the cord within each genotype. As
indicated (stars), post-hoc analysis (independent t -test or non-
parametric Mann-Whitney rank sum test) showed that, while it is only
the case at the first rostral position for the CAPs, the majority of the FPs
were significantly different between the two genotypes (p,0.05),
except for the most caudal sites (3200 to 4000 mm) where the signals
appeared greatly reduced both for WT and EphB1KO mice.
doi:10.1371/journal.pone.0053673.g002
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Microglial Activation in the Spinal Cord following PNL is
Attenuated in EphB1 KO Mice
Microglial cell activation has been shown to be associated with
the onset of neuropathic pain. We identified microglial cells with
Iba1 antibodies and manually counted the number of morpho-
logically identified activated microglial cells in the dorsal horn of
the spinal cord in control, sham animals, and in animals which
had undergone PNL, both ipsilaterally and contralaterally to the
lesion. In sham animals there was no difference in the number of
activated microglial cells in WT or EphB1 KO mice (figure 8 A,
Figure 3. EphB1 KO mice display less spontaneous pain behaviour than WT mice in the formalin test. The behavioural responses of
EphB1 KO and WT mice were examined in the formalin test. A formalin solution was injected in one of the hind paws, and the mice were observed for
60 minutes. Pain-related behaviours (lifting-favouring and licking of the injected paw) were recorded in 5 minutes intervals, and the results are
graphically represented in panels A and B. A ‘pain score’ was calculated based on these data, and is represented in panel C. The animals displayed
initially an acute response to the injection (Phase I), which is akin to acute nociception and depends upon activation of peripheral terminals of
nociceptors. This phase lasted approximately 10 minutes. After a pause of a few minutes, during which little pain related behaviour was observed, the
mice began again to lift or lick the affected paw (Phase II). When the cumulative results of EphB1 KO and WT mice for Phase I and Phase II were
compared, there was no difference between WT and KO during Phase I. However, EphB1 KO mice displayed significantly less pain related behaviours
(Lifting/favouring, licking and pain score) as compared to WT mice during Phase II. Bar charts represent mean +/2 SEM Asterisks indicate a significant
difference WT vs EphB1 KO with p,0.05 (t-test). WT n=13, EphB1 KO n= 15.
doi:10.1371/journal.pone.0053673.g003
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B). Following nerve injury, increased microglia activation was
observed in the ipsilateral dorsal horn of the spinal cord from day
3 onwards. This activation was present also in EphB1 KO mice,
but to a significantly lesser extent, as compared to WT (p,0.05).
By day 22, though, there was no significant microglial activation,
as compared to sham animals, in either WT or KO mice. We did
not observe a significant microglial activation on the contralateral
side (average number of activated microglial cells/100 mm2: day 3
WT 1.133+/20.0726, EphB1 KO 1.117+/20.0167; day 7 WT
1.083+/20.209, EphB1 KO 1.400+/20.277; day 14 WT
1.258+/20.0902, EphB1 KO 1.175+/20.142; day 22 WT
1.046+/20.123, EphB1 KO 0.917+/20.0928).
Discussion
In this study we characterised extensively EphB1 receptor KO
mice in terms of their responses to acute noxious stimuli and
susceptibility to persistent (chronic) pain, in a number of models in
which spontaneous pain behaviour and/or thermal and mechan-
ical hyperalgesia have been attributed at least in part to the
development of central sensitisation, an activity-dependent alter-
ation of synaptic connectivity within the spinal cord,. Our main
findings are 1) the EphB1 receptor is not essential for the
development of peripheral nociception, nor for thermal or
mechanical sensitivity; 2) functional EphB1 receptors are required
for the development and/or maintenance of thermal and
mechanical hyperalgesia and spontaneous pain in a variety of
pain models; 3) EphB1 receptors are necessary for the induction of
phosphorylation of the NR2B subunit of the NMDA receptor and
are involved in the increase of c-fos expression in models of
inflammatory pain and tissue injury and in microglial activation
following PNL.
EphB1 receptors, together with other Eph receptors, play an
important role in neuronal development (see e.g. [40]), therefore it
was important to establish that EphB1 KO mice were normal in
terms of development of nociceptive pathways and nociception, in
order to be suitable in models for the study of the modulation of
pain processing. This had not been examined in previous studies
using these mice. Since pain sensitivity in animal models is
measured through behavioural tests dependent on a motor
response, it was also important to test naı¨ve KO mice in
comparison to WT littermate in a motor test, particular in light
of findings indicating that EphB1 KO exhibit neuronal loss in the
substantia nigra [41]. We found no indication that this loss affected
the response to acute noxious stimuli using a variety of tests,
including thermal and mechanical stimuli, or to the first phase of
the formalin test, reflecting acute tissue damage. Gross anatomical
abnormalities were also absent from both the DRG and the dorsal
Figure 4. EphB1 KO mice display reduced thermal and mechanical hyperalgesia in inflammatory pain models. The behavioural
responses of EphB1 KO and WT mice were examined in two test of inflammatory pain. Either carrageenan (A) or CFA (B) were injected in a hind paw,
and responses to thermal (Hargreaves) and mechanical (von Frey) stimuli were recorded up to a maximum of 150 minutes (A) or 14 days (B). Thermal
sensitivity following carrageenan injection was tested in mice of two genetic backgrounds, CD1/ICR and CD1/129, and mechanical allodynia was
tested in CD1/ICR mice only. All WT mice developed thermal and mechanical hyperalgesia (p,0.05). EphB1 KO mice did not develop thermal or
mechanical hyperalgesia. Following CFA injection, which elicits a greater and more prolonged inflammatory response as compared to carrageenan,
both WT and EphB1 KO mice developed thermal and mechanical hyperalgesia (B). However, EphB1 KO mice displayed a faster recovery in terms of
thermal hyperalgesia and a significantly smaller development of mechanical allodynia. * p,0.05 vs respective baseline,# p,0.05 comparing WT and
EphB1 KO mice at equivalent time points (Repeated Measures ANOVA followed by Multiple Comparisons versus Control Group, Holm-Sidak method).
A) CD1/ICR Hargreaves WT n= 9, EphB1 KO n= 9, von Frey WT n= 10, EphB1 KO n= 10; CD1/129 WT n= 8, EphB1 KO n= 6; B) n = 8 for all groups
except EphB1 KO in the von Frey test, where n= 9.
doi:10.1371/journal.pone.0053673.g004
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horn of the spinal cord. Similarly electrophysiological recording at
the cord dorsum, measuring the spatial distribution and ampli-
tudes of the CAPs and FPs following sciatic nerve stimulation, did
not reveal any difference between WT and EphB1 KO mice in
terms of somatotopic organisation of sensory projections in the
spinal cord. Although the presence of developmental defects in
glutamatergic synapses in the hippocampus of transgenic EphB2
KO mice remains unclear [42,43], it is possible that in single
mutants (EphB1 or EphB2 receptors KO) compensatory mecha-
nisms, due to the presence of other EphB receptors, which bind
promiscuously to the same ephrinB ligands, may allow a
comparatively normal development. We cannot however exclude
the presence of subtle changes, for example at the level of the
glutamatergic synapses of sensory afferents onto dorsal horn
neurons, below the level of detection behaviourally. In this respect
our finding of enhanced sural nerve evoked superficial dorsal horn
FPs is of relevance in that it indicates such a change in the
connectivity of Ab-fibres. Our simplest explanation for this finding
draws on the changes observed early postnatally in the rat where
the predominant A-fibre innervation of the superficial dorsal horn
at birth undergoes a dramatic, activity-dependent withdrawal of
the nerve terminals to deeper layers over the first postnatal weeks
[44,45]. It is proposed here that such functional and structural
reorganisation did not occur in EphB1KO mice. Further studies
are needed to determine whether inhibitory or excitatory
interneurons, projection neurons or both, are involved in this
refinement process. Although this change in the connectivity of A
fibres in the sural nerve is of considerable interest in view of the
guidance role of Eph receptors during development, it had no
demonstrable impact on the behavioural tests we employed, or on
Figure 5. Upregulation of c-fos expression following formalin or carrageenan injection is reduced in EphB1 KO mice. C-fos
immunoreactivity was examined in EphB1 KO and WT mice following formalin and carrageenan injection. Saline injected animals were used as
controls. (A) photomicrographs of section of lumbar spinal cord of EphB1 KO and WT mice injected with formalin, carrageenan or saline as indicated,
immunostained with anti c-fos antibodies. B) c-fos positive cells were counted in lumbar cord section of mice treated as in (A). Saline treated animals
had none or few c-fos positive cells. Both formalin and carrageenan injection induced a significant increase in the number of c-fos positive cells in WT
mice (two-way ANOVA followed by multiple comparisons, Holm-Sidak method, for carrageenan, t-test for formalin experiments), but carrageenan or
formalin injection caused a significantly lower increase in EphB1 KO mice. * p,0.05 vs respective saline,# p,0.05 vs WT. For all experimental groups
n = 3.
doi:10.1371/journal.pone.0053673.g005
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the gross anatomical connectivity of C and Ad fibres. Another
possible explanation for the enhanced synaptic transmission we
observed could be a change in the electrophysiological properties
of the large diameter Ab-fibre, as described in DRG neurons for a
rat model of osteoarthritic pain [46] and more recently in a
neuropathic pain model [47].
Clearly indicated for future work would be a comparison of a),
the cord dorsum CAP and field potentials evoked by fibres in the
sural and saphenous nerves; b), their depth profiles in the dorsal
horn as this would provide direct evidence of a developmentally –
based shift in their sites of termination and/or or their synaptic
strength.
Following our initial work demonstrating an involvement of
EphB receptors-ephrins interaction in modulation of pain
processing in the spinal cord [7], a growing number of other
studies has provided evidence supporting a role of EphB receptors
in a variety of short-term inflammatory and longer-term, chronic
pain models (carrageenan and formalin injection in the hind paw,
chronic constriction injury, pain induced by morphine withdrawal
in dependent animals, cancer pain, see e.g. [9,24,48–52] ).
Initially, the unequivocal identification of the specific EphB
receptor involved had been impossible, due to the lack of suitable
reagents and in particular specific agonists and antagonists. A
study by Han et al. [25], performed on one of the strains of EphB1
KO mice used here, confirmed the hypothesis of an involvement
of EphB1 receptors in neuropathic pain (thermal hyperalgesia in
the CCI model) and in physical dependence to morphine,
comparing the behavioural responses of EphB1 KO, heterozygous
and WT mice. In their study, a complete lack of development of
thermal hyperalgesia was observed in EphB1 KO mice in the CCI
model. Here, we examine the EphB1 KO mice studied by Han
et al. in a number of other models, including short-term
(carrageenan injection) and long-term (CFA injection) inflamma-
tion, tissue damage and PNL. Even if the molecular and cellular
mechanisms underlying hypersensitivity in experimental models of
pain have not been completely clarified, it is clear that different
molecular and cellular mechanisms underlie hypersensitivity in
different pain models (see e.g. [23]), and also mechanical and
thermal hyperalgesia in the same model; for example, with regard
to neuropathic pain, it has been shown that there are significant
differences in the mechanisms leading to chronic pain in different
models [53,54], and in the mechanisms leading to the induction of
thermal and mechanical hyperalgesia. It is therefore important to
establish if and to what extent EphB1 receptors contribute to
thermal and mechanical hyperalgesia, as well as spontaneous pain
behaviour, in pain states of different aetiology.
Figure 6. Lack of increase in NR2B phosphorylation in EphB1 KO mice following formalin or carrageenan injection. Tyrosine
phosphorylation of the NR2B subunit of the NMDA receptor was analysed by immunoprecipitation followed by Western Blotting in WT and EphB1 KO
mice after injection with formalin or carrageenan. Saline injected animals were used as controls. Spinal cords were dissected from injected animals
1 h (A) or 3 hours (B) after injection. Representative immunoblots are shown in the top part of panels A and B. In panel A, the last two columns
represent positive (mouse brain tissue) and negative (immunoprecipitation of mouse brain tissue conducted in the absence of anti-NR2B antibodies)
controls of the immunoprecipitation and Western blotting protocol. The blots were quantified, and the ratio of phosphoTyr to the total NR2B present
was calculated. The bar charts in the bottom half of panels A and B show the mean and SEM of the levels of phosphoNR2B present in EphB1 KO and
WT mice following injection with Formalin, Carrageenan or saline, as indicated. There was a significant increase in Tyrosine phosphorylation of NR2B
in WT mice following formalin (A) and carrageenan injection (B), p,0.05. There was no change in the level of NR2B phosphorylation in EphB1 KO
mice following either injection. Comparisons performed with t-test for WT in the formalin experiment and EphB1 KO in the carrageenan experiments,
with Mann-Whitney U-test in the remaining experiments. * p,0.05 vs respective saline. For all experimental groups n = 3, except in A) EphB1 KO
saline n= 4.
doi:10.1371/journal.pone.0053673.g006
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In a number of models (CCI and carrageenan injection) we
observed a complete lack of development of mechanical and
thermal hyperalgesia, as we expected on the basis of previous
findings obtained in rats treated with the EphB receptor blocker
EphB1-Fc (for carrageenan injection and thermal hyperalgesia in
CCI; [7,9]) or in EphB1 KO mice (for thermal hyperalgesia in
CCI; [25]).
However, in the CFA-induced inflammatory pain model
hyperalgesia and allodynia developed almost normally in KO
mice, but recovery was accelerated. This is particularly interesting
because due to its duration the CFA model would arguably be one
of the most clinically relevant. Furthermore, this finding was
partially replicated in the PLN model of neuropathic pain where
thermal hyperalgesia developed almost normally in KO mice, but
recovery was accelerated. The results obtained in the CFA and
PNL models indicate that EphB1 receptors play a significant role
in maintaining sensitisation hence emphasising their importance as
a potential therapeutic target.
The behavioural findings reported here are evidence of a crucial
role of EphB1 receptors in the onset and/or maintenance of
thermal and mechanical hypersensitivity in a variety of models of
pain, but what are the specific cellular and molecular mechanisms
involved? Notwithstanding the number of differences in the
molecular and cellular changes they induce, in all of the models we
have used, a supposed common mechanism is represented by
classical central sensitisation, an activity-dependent increase in the
strength of synaptic transmission between primary sensory
afferents and dorsal horn neurons [12]. Although such sensitisa-
tion is thought to be an NMDA receptor-mediated process, its
mode of modulation is not yet fully understood. LTP at C-fibre
synapses on a subpopulation of nociceptive neurons in lamina I of
the dorsal horn could also contribute to pain amplification [14,15].
Phosphorylation of NMDA receptor subunits has been proposed
to lead to increased Ca++ entry through the receptor, both in
central sensitisation and in NMDA dependent LTP [19,55]. Liu
et al. [56] showed that uncoupling Src from the NMDA receptor
Figure 7. Accelerated recovery from mechanical and thermal hyperalgesia following nerve injury in EphB1 KO mice. Behavioural
responses following peripheral nerve lesion were examined in EphB1 KO mice and WT mice. Two models of nerve injury were used, partial nerve
lesion (PNL) and chronic constriction injury (CCI). Development of both thermal and mechanical hyperalgesia were studied after PNL, mechanical
hyperalgesia only was examined after CCI. WT mice developed significant thermal hyperalgesia in both models. In WT mice with PNL, hyperalgesia
developed by 3 days after injury and persisted throughout the duration of the experiment. This reduction in paw withdrawal latency was significantly
smaller in EphB1 KO mice at all time points, except 5 days after injury. WT mice also developed mechanical allodynia with a marked decrease in
stimulus intensity required to trigger a lifting response of the injured paw as compared to baseline. EphB1 KO mice displayed a less pronounced
mechanical allodynia when compared to WT at all time points (p,0.05). In the CCI model mice responses to mechanical stimuli were tested at 7, 14
and 21 days after injury. WT mice developed a significant mechanical allodynia by 7 days (p,0.05), and this persisted throughout the experiment,
whilst EphB1 KO mice failed to develop a significant mechanical allodynia.* p,0.05 vs respective baseline, # p,0.05 vs WT. Test: repeated measures
ANOVA followed by multiple comparisons, Holm-Sidak method. PNL WT n=6, EphB1 KO n= 9; CCI WT n= 7, EphB1 KO n= 5.
doi:10.1371/journal.pone.0053673.g007
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complex, thus preventing NMDA tyrosine phosphorylation,
suppresses inflammatory and neuropathic pain. Phosphorylation
of the NR2B subunit has been claimed to be important for the
onset of persistent pain, however there is evidence both in favour
and against NR2B involvement, particularly in inflammatory pain
(in favour [8,19,20,57,57,58] [59]; against [18,20,60]).
Guo et al. [19] were the first to propose that NMDA receptor
phosphorylation in central sensitisation could be modulated by
other receptors, rather than simply by activation of the NMDA
receptor itself (with consequent activation of Src tyrosine kinases);
and they were also the first to show NR2B tyrosine phosphory-
lation in CFA induced inflammatory pain. Work from our
laboratory had suggested a role for EphB receptors in central
sensitisation, showing that, in analogy with what had previously
been demonstrated in cultures of embryonic cortical and
hippocampal neurons [27], EphB receptor activation could lead
to NR2B subunit phosphorylation in the spinal cord, a process
mediated by the activation of the non-receptor tyrosine kinase Src
[8]. Furthermore, in a model of acute inflammatory pain
(carrageenan injection) in adult rats [8] and also in the formalin
model in adult mice [49], we showed NR2B tyrosine phosphor-
ylation in the spinal cord following injection, in contrast to the
findings of Caudle et al. [18], who found that the NR2B receptor
is not involved in inflammatory pain. Liu et al. [52] replicated our
finding showing that EphB receptor activation in rats induces
NR2B phosphorylation, but also showed that blocking receptor
activation with EphB2-Fc chimera (which blocks the activation of
all EphB receptors) prevented the increased phosphorylation of
NR2B in a model of cancer pain. On the basis of the findings
reported in the literature, and discussed above, and in particular
[7,8,27,52], we hypothesised that in WT type mice inflammation
or tissue injury may lead to activation of EphB1 in dorsal horn
neurons, with consequent phosphorylation of NR2B; lack of
functional EphB1 receptor would therefore abolish such increased
phosphorylation. The findings reported here are consistent with
the hypothesis that NR2B subunit phosphorylation is indeed
downstream of EphB1 receptor activation in both the carrageenan
model and in the formalin model, in which NR2B is tyrosine
phosphorylated in WT but not in KO mice. However, our findings
also provide support for the conflicting hypothesis [18],that NR2B
phosphorylation is not required for the onset of chronic pain, since
in some long-term models we observed the onset of hyperalgesia
and allodynia also in EphB1 KO mice. We attempted to analyse
NR2B phosphorylation in a longer duration model (CFA), using
naive mice, and mice at 1, 7 and 14 days after injection of CFA or
saline. Despite using 8 mice/genotype/timepoint (2 mice/sample),
our results were inconclusive, with no obvious increase in NR2B
phosphorylation in EphB1 KO mice, and a non-significant, 20%
increase in phosphorylation in WT mice at 1 day only (data not
shown). This would be consistent with the time course of NR2B
phosphorylation in the spinal cord of rats, following CFA injection,
reported by Guo et al. [19] but needs to be confirmed. The
biochemical analysis of NR2B receptor phosphorylation in the
mouse spinal cord is challenging, possibly due to low levels of the
receptor as a proportion of total protein level; further investiga-
tions on the link between EphB1 receptors, NR2B phosphoryla-
tion and chronic inflammatory and neuropathic pain could
probably more profitably investigated with genetic manipulation,
for example by crossing EphB1 mutants with mice in which NR2B
cannot be phosphorylated on tyr1472, which have been shown to
develop attenuated neuropathic pain [20], or by developing a
spatially and time restricted NR2B knockout, similar to the one
generated for NR1 [17,61]. This second alternative may give
different results from those obtained in mutants in which tyr 1472
cannot be phosphorylated, since there are two other tyrosine
phosphorylation sites on NR2B (tyr1252 and tyr 1336), which may
play a role. It is however worth noting that NMDA-dependent
synaptic plasticity in the hippocampus was shown to be
independent of EphB2 receptor kinase activity, despite requiring
the extracellular portion of the receptor [42,43], in contrast to the
requirement for kinase activity shown by Takasu et al. [27] in
embryonic neurons in culture. It is therefore possible that EphB1
receptors may mediate alterations in spinal cord processing of pain
independent of their kinase activity.
The immediate early gene c-fos has been shown to be expressed
in neurons of the dorsal horn following activation of nociceptive
pathways [62,63], and Takasu et al. [27] showed increased c-fos
expression following EphB receptor activation in cultured
embryonic cortical and hippocampal neurons. We previously
showed increase in c-fos-positive cells in the superficial laminae of
the dorsal horn in carrageenan treated rats, an increase which was
not present when EphB1-Fc was injected intrathecally prior to
carrageenan injection, thus linking EphB1 receptor activation to c-
fos expression also in vivo. Liu et al. [26] demonstrated increased
Figure 8. Microglial activation following PNL is attenuated in
the spinal cord of EphB1 KO mice. In (A) representative
immunostaining for Iba1 in the superficial laminae of the dorsal horn
of the spinal cord 3 days after PNL, or in sham operated animals. The
hemicord ipsilateral to the sciatic nerve partial ligation is shown. In (B)
bar chart illustrating cell counting for Iba1 positive cells in the dorsal
horn. An increase in microglia cell activation was shown after PNL in
both WT and EphB1 KO mice at 3, 7 and 14 days after lesion (p,0.05).
However, the increase of immunoreactivity for Iba1 was attenuated in
EphB1 KO mice (p,0.05 overall, and at 3 and 7 days after lesion). Data
shown as mean 6 SEM. * p,0.05 vs respective sham, # p,0.05 vs WT.
Test: two-way ANOVA followed by multiple comparisons, Holm-Sidak
method. WT and EphB1 KO n=3 for each timepoint.
doi:10.1371/journal.pone.0053673.g008
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c-fos expression in the dorsal horn of mice following high
frequency stimulation of C fibres in vivo. This was prevented by
EphB2-Fc pre-treatment and in EphB1 KO mice. Furthermore,
Liu et al. [10] showed NR2B phosphorylation and increased c-fos
expression in the dorsal horn in a morphine withdrawal model.
Both increases were prevented by blocking EphB receptor
activation with EphB2-Fc. Here, we show that both formalin
and carrageenan injection induce an increase in c-fos expression in
WT but a significantly smaller increase in EphB1 KO mice. This
suggests that c-fos upregulation may mediate some of the effect of
EphB1 activation on pain sensitivity. We cannot directly link the
increase in c-fos expressing neurons to NR2B phosphorylation,
since we cannot demonstrate that the neurons expressing c-fos are
the same in which NR2B is phosphorylated. Hopefully technical
improvement in immunohistochemical approaches will allow
doing so in the future. However the findings by Takasu et al
[27] in culture, together with the indirect evidence from the
in vivo studies cited above, would suggest that c-fos upregulation is
likely to be linked, at least in part, to increased NMDA receptor
activity.
We did not comprehensively investigate c-fos expression in
neuropathic pain models, since published results on c-fos
expression in neuropathic pain models, particularly in the chronic
phase, have been extremely inconsistent, even in the rat, which has
been studied fairly extensively [64]. However, instead, we did
examine one of the potential cellular mechanism, through which
EphB1 deficiency may modulate neuropathic pain, based on a
growing body of evidence implicating microglial activation in
neuropathic pain, which would lead to pro-inflammatory
responses with pathological effects [28,65]. We therefore counted
activated microglia in the dorsal horn of the spinal cord of WT
and EphB1 KO mice following PNL. Possibly due to the fact that
many of the studies on the molecular mechanism regulating
microglial activation have been conducted in vitro, the precise
nature of the cellular and molecular mechanisms regulating this
activation in vivo is still poorly understood, but the current
consensus is that activation is triggered by signals coming from
primary afferents, with prominent candidates being ATP and
monocyte chemoattractant protein-1 (MCP-1), followed by
neuronal factalkine, cleaved by Cathepsin S of microglial origin
[28,66], Furthermore, input from A fibres has been shown to be
important for microglial activation in the spared nerve model [67].
None of these mechanisms should be affected by lack of EphB1
receptors. However, microglial activation was attenuated in
EphB1 KO mice from day 3, in parallel with the observed
attenuation of thermal and mechanical hyperalgesia. This would
suggest that the EphB1 receptor is implicated in the mechanisms
leading to microglia activation in neuropathic pain, even though
other mechanisms, independent of EphB1 receptor expression,
must be involved, since some level of microglial activation was
present also in KO mice. We had observed an analogous
reduction in microglial activation in a conditional knockout
(generated in a different mouse strain), lacking ephrinB2
specifically in a subpopulation (largely nociceptive) of DRG
neurons [49], confirming that the observations made here in
EphB1 KO mice cannot be due to the lack of presumptive pre-
synaptic EphB1 receptors. This would indicate that microglial
activation must be at least in part mediated by post-synaptic
mechanisms. Daulhac et al. [68] observed, in a model of diabetic
neuropathy, that microglia activation was dependent on NMDA
receptor activity. The findings presented here would suggest that a
similar mechanism may also be at work in our injury model of
neuropathic pain, since lack of EphB1 receptors can affect NMDA
receptor function. Further studies should be carried out on these
potential post-synaptic mechanisms, also to determine if they
contribute to microglial activation in all types of pain. In contrast
to Dauhlac et al. findings in diabetic neuropathy, Cheng et al,
[69] observed NMDA-independent microglia activation in CFA-
induced inflammatory pain.
Interestingly, both thermal and mechanical hyperalgesia are still
present at day 21 in WT, and to a lesser extent in EphB1 KO
mice, when microglial activation is no longer detectable,
supporting the hypothesis that microglial activation is important
for the early phases of neuropathic pain, rather than long-term
maintenance.
Our findings can be explained in their entirety by postulating an
exclusively post-synaptic site of action for EphB1 receptors.
Nevertheless two of the studies by Song’s group [9,25] would
suggest that, at least in the CCI model, there may be an
involvement of pre-synaptic EphB1 receptors in the behavioural
responses observed. They demonstrated hyperexcitability of DRG
neurons following CCI, which was not present in EphB1 KO mice
and which could be blocked by EphB1-Fc. Also in rats CCI led to
increased expression of EphB1 in DRG neurons. Kobayashi et al.
[24] suggested the presence of ephrin B2 in spinal cord neurons,
and this could potentially activate EphB1 receptors on DRG
neurons. Any pre-synaptic role of EphB1 receptors is however
likely to be in addition to, rather than in alternative, to a post-
synaptic role, since both EphB1 and NMDA receptors have been
shown to be present in dorsal horn neurons, and can be
immunoprecipitated together from the spinal cord. Crucially, in
a nociceptor-specific ephrinB2 deficient mouse we showed a
reduced phosphorylation of NR2B in the formalin and PNL
models [49]. This reduction could not be mediated by pre-synaptic
EphB1 receptors, since their potential ephrinB2 ligands in the
spinal cord are still present in the ephrin B2 nociceptive specific
KO. Also, the findings we reported with ephrin B2 nociceptive
specific KO mice allow us to exclude that the results we report
here may be due to EphB1 receptors in the dorsal horn acting by
activating reverse signalling via pre-synaptic ephrinB2; as men-
tioned in the introduction, EphB receptor-ephrinB interactions
may activate both forward signalling via the receptor, and reverse
signalling via the transmembrane ligand, and there is evidence,
mainly in the hippocampus, that ephrin signalling may modulate
synaptic function [6].
Moreover, it is not clear whether any possible role played by
EphB1 receptors in DRG neurons would be at the level of central
synapses, or rather in the periphery, where at least in the case of
tissue damage models (formalin), peripheral EphB receptors
appear to be important [70]. It is however worth noticing that
the role identified by Cao et al. [70] for EphB receptors in the
periphery may not be mediated entirely (or at all) by EphB1
receptors, but by another EphB receptor. Intraplantar injection of
EphB1-Fc (which would block any EphB receptor) reduced pain-
related behaviour in both phase I and phase II in Cao et al.’s
experiments, whereas in EphB1 KO mice the response in Phase I
is not affected. A peripheral site of action for EphB1 receptors on
DRG neurons could still explain the differences in excitability
observed by Han et al. [25] in injured EphB1 KO mice.
Conclusions
Independently of the differences we observed in the extent of
the effect of the lack of functional EphB1 receptors in a variety of
inflammatory, tissue and nerve injury models, in all cases we found
that the lack of EphB1 protein led to a blunted or absent thermal
and mechanical hyperalgesia, or spontaneous pain behaviour. It
would therefore appear likely that the induction and/or mainte-
nance of central sensitisation require the presence of EphB1
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receptors, regardless of cause and sensory modality examined.
Cellular and molecular mechanisms that mediate the role of
EphB1 in leading to increased sensitivity/spontaneous pain are
likely to include NR2B phosphorylation,increased c-fos expression
and microglial activation. Our present findings confirm the
identity of the EphB receptors involved in the onset of various
types of persistent, chronic pain as the EphB1 receptors, extend
the involvement of EphB receptors to models of long term
inflammation and the Seltzer neuropathic pain model, suggesting
that this receptor is probably involved in all forms of allegedly
NMDA-dependent persistent pain. Intriguingly, in models of
persistent pain we observed that EphB1 KO mice developed
hyperalgesia/allodynia, but recovered faster as compared to WT
mice, suggesting that the EphB1 receptor may be an attractive
target for the development of analgesic strategies.
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